AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Eisai and Biogen Present New Data on LEQEMBI's Effectiveness in Reducing Neurotoxic Aβ Protofibrils in CSF.
ByAinvest
Tuesday, Dec 2, 2025 4:41 pm ET1min read
Eisai and Biogen presented data at the CTAD Conference 2025, confirming the pharmacological effect of LEQEMBI (lecanemab-irmb) on Aβ protofibrils in CSF. The study demonstrated that lecanemab binds to PF, mitigating their toxic effects and slowing Alzheimer's disease progression. The data showed a statistically significant increase in total CSF PF concentration with lecanemab treatment compared to placebo, and a correlation between PF changes and neurodegeneration biomarkers was observed in the placebo group but not with lecanemab treatment.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet